Search

Your search keyword '"Davor Štimac"' showing total 5 results
Start Over Author "Davor Štimac" Journal gastroenterology
5 results on '"Davor Štimac"'

1. Are levels of alkaline phosphatases and bilirubin surrogate markers of outcomes of patients with primary biliary cirrhosis?

Author

Davor Štimac, Christian Gluud, and Vanja Giljaca

Subjects
Male, medicine.medical_specialty, Hepatology, business.industry, Bilirubin, Liver Cirrhosis, Biliary, Phosphatase, Gastroenterology, medicine.disease, Alkaline Phosphatase, chemistry.chemical_compound, Alkaline phosphatase blood, Primary biliary cirrhosis, chemistry, Internal medicine, medicine, Humans, Female, business, laboratory biomarkers
Abstract

U pismu upućenom uredniku dan je komentar na naslovljen originalni znanstveni rad vezano uz primarnu bilijarnu cirozu i primjenu laboratorijskih biomarkera u procjeni iste.

Published
2014

2. Su2091 Results of a Phase II, Randomized, Double Blind, Controlled Trial of the Efficacy of Active Therapeutic Immunization With TNF-Kinoid in Patients With Moderate to Severe Crohn's Disease With Secondary Resistance to TNFα Antagonist

Author

Max Reinshagen, Peter R. Hoffmann, Davor Štimac, Yoram Bouhnik, Jean-Frederic Colombel, Jean-Louis Dupas, Pierre Vandepapelière, Adriaan A. van Bodegraven, Martin Goetz, Andrea Pace, Jochen Klaus, Jan Bures, Geert R. D'Haens, Stefanie Howaldt, Sandrine Kahi, Stefan Schreiber, Paul Rutgeerts, Xavier Hébuterne, Severine Vermeire, Olivier Dewit, and Matthieu Allez

Subjects
Moderate to severe, medicine.medical_specialty, Crohn's disease, Tnfα antagonist, Hepatology, business.industry, Gastroenterology, medicine.disease, law.invention, Double blind, Randomized controlled trial, Immunization, law, Internal medicine, Medicine, Tumor necrosis factor alpha, In patient, business
Published
2012
Full Text
View/download PDF

4. 391 Both Budesonide (9mg) As Well As High-Dose Eudragit-L-Coated Mesalamine (4.5g) Lead to High Remission Rates in Moderately Active Crohn's Disease Patients: A Double-Blind, Double-Dummy, Randomized, Multicenter Study

Author

Simon Bar-Meir, Jan Kykal, Libor Gabalec, Davor Štimac, Ioannis E. Koutroubakis, Ivan Bunganic, Eva Tomsová, Milan Lukas, Marian Bátovský, István Altorjay, Hanns F. Löhr, Bohumil Fixa, Rifaat Safadi, Ralf Mohrbacher, A. Tromm, Heinz-Jochen Kramm, Roland Greinwald, and Zsolt Tulassay

Subjects
Budesonide, Crohn's disease, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, medicine.disease, Eudragit L, Double blind, Multicenter study, Internal medicine, medicine, business, Lead (electronics), medicine.drug
Published
2009
Full Text
View/download PDF

5. Fontolizumab (Huzaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn’s disease

Author

T. Pearce, Mária Zakuciová, Gert Van Assche, S. Stoinov, János Lonovics, Davor Štimac, Geert R. D'Haens, Daniel W. Hommes, Boris Vucelić, and Tatiana Mikhajlova

Subjects
Moderate to severe, Crohn's disease, Hepatology, biology, business.industry, Gastroenterology, medicine.disease, Tolerability, Immunology, medicine, biology.protein, Fontolizumab, Antibody, business, Ifn gamma, medicine.drug
Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results